National Webinar- Biosimilars: To Switch or Not To Switch

January 31, 2019 1:00 PM to 2:00 PMOnline - Eastern Time Zone
Area of Interest: Benefits Format: Web

This session will look at Canada's progress with biosimilar adoption and what public/private payors are doing to support their introduction into the Canadian healthcare environment.

Ned Pojskic, Leader, Pharmacy & Health Provider Relations at Green Shield Canada, will discuss why there is such low patient uptake in Canada, and what strategies exist today to increase biosimilar utilization. Ned will take a look at the increasing body of evidence – both from clinical trials and registries (real-world evidence) – that supports transitioning patients to biosimilars, and he will share what a biosimilar transition program can look like, from both a patient experience and plan sponsor savings perspective.

Cheryl Koehn, Founder and President of Arthritis Consumer Experts, will provide a patient’s perspective on biosimilars and more specifically biosimilar transitioning, including Arthritis Consumer Experts’ position on this important topic. Cheryl will also discuss the nocebo effect and the evidence that guides how to have the most appropriate conversation with patients to mitigate this effect.

Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance Office, will outline the Pan Canadian Pharmaceutical Alliance’s (pCPA’s) recently released policy directions for biologics, as they apply to pCPA negotiations.

What you will learn:

  1. Elaborate the clinical evidence supporting biosimilar transitioning both from clinical trial and real world evidence

  2. Explore how jurisdictions around the world are embracing biosimilars through formulary management

  3. Outline the Canadian payer experience with biosimilar transitioning

  4. Gain understanding about the nocebo effect as it relates to transitioning from a biologic originator to a biologic biosimilar;

  5. Identify key conversation characteristics that result in a positive biosimilar transition experience between health care professionals and patients;

  6. Identify key aspects of PCPA’s policy directions as it relates to biosimilar and originator products

Who should attend

Plan sponsors, plan advisors, brokers, consultants, TPAs

You can now register to access the recording 

This session will look at Canada's progress with biosimilar adoption and what public/private payors are doing to support their introduction into the Canadian healthcare environment. Ned Pojskic will discuss why there is such low patient uptake in Canada, and what strategies exist today to increase biosimilar utilization. Ned will take a look at the increasing body of evidence – both from clinical trials and registries (real-world evidence) – that supports transitioning patients to biosimilars, and he will share what a biosimilar transition program can look like, from both a patient experience and plan sponsor savings perspective.

Fees and Registration
Membership Types Regular Price Plan Sponsor Price
Regular membership $0.00 CDN $0.00 CDN
Plan Sponsor Individual Membership $0.00 CDN $0.00 CDN
Associate $0.00 CDN $0.00 CDN
Student $0.00 CDN -
Non Member $90.00 CDN $65.00 CDN
Cancellation Policy
CE credits are offered in partnership with La Chambre de sécurité financière, The Institute, Insurance council of Manitoba, Saskatchewan, Alberta and BC

Ned Pojskic,  HonBSc, MSc, PhD
Leader, Pharmacy & Health Provider Relations
Green Shield Canada

Ned Pojskic is Green Shield Canada’s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC’s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.

With an industry background that includes a role as Director of Health Policy for the Ontario Pharmacists Association, Ned is a key member of GSC’s Strategic Market Solutions Team. Ned holds Masters and PhD degrees from the Department of Pharmaceutical Sciences at the University of Toronto and is currently appointed as an adjunct professor within the Leslie Dan Faculty of Pharmacy.

CHeryl Koehn

Cheryl Koehn
Founder and President
Arthritis Consumer Experts

Ms. Cheryl Koehn is an arthritis advocate, community leader, published author and rheumatoid arthritis survivor for 30 years. She has dedicated her life to helping others living with arthritis as well as people with other chronic diseases. She is the founder and president of Arthritis Consumer Experts, a national, patient-led organization that provides science-based information and education programs in both official languages to people with arthritis. She served as Founding Chair of the Consumer Advisor Council of the Canadian Arthritis Network, was the Patient Co-Chair of the Summit on Standards for Arthritis Prevention and Care, and the first patient to be named to a federal scientific peer review committee as full voting member and on the Canadian Institutes of Health Research Standing Committee on Ethics.

Ms. Koehn served as the consumer (patient) representative board member of the Arthritis Alliance of Canada, is a past board member of the Arthritis Research Canada, and served in a leadership capacity on numerous other national organizations and committees. As one of North America's leading arthritis advocates, Ms. Koehn provides a patient perspective on arthritis health and policy issues across Canada to governments, private payers, healthcare professionals, and media. She is frequently invited to speak at national and International arthritis and health-related conferences.

With her team at Arthritis Consumer Experts, Ms. Koehn has led the development of numerous information and education innovations to the arthritis community, including the ArthritisID and Arthritis ID PRO iPhone apps, the blog site Arthritis Broadcast Network, the annual report card on provincial formulary performance for inflammatory arthritis medications, Canada's Best Workplaces for Employees Living with Arthritis Award, and most recently, JointHealth Education, a series of on-line “courses” graduating today’s modern arthritis patient.

Along with co-authors Dr. John Esdaile and Taysha Palmer, Cheryl Koehn authored Rheumatoid Arthritis: PLAN TO WIN, published by Oxford University Press in January 2002. She lives in Vancouver, British Columbia, Canada, where she enjoys ocean swimming, cycling and walks with friends and her faithful dog, Molly.

Imran Ali

Imran Ali
Senior Manager
pan-Canadian Pharmaceutical Alliance (pCPA) Office,

Imran Ali is the Senior Manager of the pan-Canadian Pharmaceutical Alliance Office and has been in the role since September 2015. From 2012 to 2015, Imran held the position of Senior Manager with the Agreements & Negotiations Unit in the Ontario Ministry of Health and Long-Term Care’s Negotiations Branch. In this role, Imran provided leadership and direction for planning, priority setting and negotiation of accountability agreements with individual providers and health care organizations to optimize the Ministry’s investment in the health care system valued at over $11 billion annually. Imran provided support for the negotiations process with the Ontario Medical Association (OMA). Prior to this, Imran supported the negotiations of the 2012 Physician Services Agreement with the OMA and lead the coordination of subsequent implementation activities related to the agreement. He also served as the Ministry Co-Chair for the Systems Management Committee, which is responsible for bilateral monitoring and analysis of physician services in Ontario with the OMA. Imran began his career with the Ministry in 2006 with the Primary Health Care Branch where he managed physician services contracts valued in excess of $50 million annually in the Specialized Models Unit. Imran graduated with a Masters in Public Health specializing in Health Policy and Management from the University of Alberta's School of Public Health in 2005.